Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Yuan Chen
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
SUMO Biosciences, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Yuan Chen is the Principal Investigator on this research project, and holds an equity interest in SUMO Biosciences, LLC, a privately-held company. In addition, Dr. Chen serves as CEO and a Board of Directors member of the company. The City of Hope Conflict of Interest and Commitment Committee (“COICC”) has determined that Dr. Chen’s interests in Sumo Biosciences, LLC, relate to the grant as the research centers on elucidating the role of SUMOylation in underlying proteasome inhibitor resistance in multiple myeloma. If the mechanism of resistance can be attributed to SUMOylation, the use of SUMOylation inhibitors could provide a new and valuable therapeutic approach for the treatment of proteasome inhibitor refractory multiple myeloma. SUMO Biosciences, LLC has a similar business goal related to examining SUMOylation and SUMOylation inhibitors. As the role of SUMOylation in cancers becomes increasingly important, the value of the company could increase as well.
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma
PROJECT NARRATIVE The proposed studies are aimed at investigating the roles of SUMOylation in regulating c-Myc and proteasome activity in multiple myeloma.
Filed on September 24, 2018.
Tell us what you know about Yuan Chen's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Yuan Chen filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Yuan Chen | Beckman Research Institute/city of Hope | Conflict of Interest | SUMO Biosciences, LLC | $100,000 - $149,999 |
| Yuan Chen | Beckman Research Institute/city of Hope | Conflict of Interest | SUMO Biosciences LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.